JMIR Dermatology

This study investigates the application of ChatGPT, an artificial intelligence tool, in providing information on skin toxicities associated with cancer treatments. The study utilized 40 questions, split between patient-oriented and oncologist-oriented, to assess the accuracy and comprehensiveness of ChatGPT's responses. Three oncodermatology specialists from a New York tertiary academic institution evaluated the responses, which showed high accuracy and comprehensiveness. However, the reading level of the responses was at the college level, potentially limiting their accessibility to patients. The study highlighted that while ChatGPT can serve as a valuable resource for clinicians, its use for patient education requires careful consideration due to the complex nature of the information provided. There were also some concerns about the need for evidence-based and up-to-date clinical recommendations. Despite these challenges, ChatGPT demonstrates potential as a supplementary tool for oncologists and dermatologists in managing and educating about cancer treatment-related skin toxicities.

The use of third party applications such as Figure 1 was found to be utilized predominately by non-dermatologist medical personnel for collaboration in medical decision making of dermatologic conditions with other providers. This discovery calls to attention the need for more readily resources for non-dermatologist health care providers when faced with skin related conditions, added benefit of trained dermatologists as adversaries to such medical application platforms, and recognition for when additional consultation or referral to trained dermatologists for more complex cases is deemed appropriate.

Continuous glucose monitoring (CGM) and continuous subcutaneous insulin infusions (CSII) are the current standard treatment devices for type 1 diabetes (T1D) management. With a high prevalence of T1D beginning in pediatrics and carrying into adulthood, insufficient glycemic control leads to poor patient outcomes. Dermatologic complications such as contact dermatitis, lipodystrophies, and inflammatory lesions are among those associated with CGM and CSII, which reduce glycemic control and patient compliance.

September 01, 2023, marked the loss of iconic singer-songwriter Jimmy Buffett after a lengthy battle with lymphoma precipitating from Merkel cell carcinoma (MCC). Given Buffett’s prominent status, media coverage of his death was extensive.

TikTok's social media platform can educate users about dermatology, but this longitudinal analysis of Skin of Color (SoC)-related TikTok hashtags from 2021 to 2022 suggests that non-dermatologist influencers continue to dominate content creation, highlighting the need for more participation from board-certified dermatologists to actively counter misinformation and address potential disparities in SoC healthcare.

Teledermoscopy has demonstrated benefits such as decreased costs and enhanced access to dermatology care for skin cancer detection. However, the heterogeneity among teledermoscopy studies hinders the systematic reviews’ synopsis of diagnostic outcomes, impeding trust and adoption in general practice and limiting overall health care benefits.

Limited data exist on the motivations and expectations of participants when enrolling in dermatology clinical trials, including melanoma early detection trials. Understanding participant motivators for research engagement has been identified as a prioritized area for trial methodology research.

Analyses of women dermatology literature authorship from 2018 to 2022 reveal a slight increase in total female authors, female first authors, and female senior authors with no substantial immediate impact of COVID-19 on current trends, encouraging future examination of long-term effects and ongoing promotion of systemic initiatives to support gender equity.

Analyses of women dermatology literature authorship from 2018 to 2022 reveal a slight increase in total female authors, female first authors, and female senior authors with no substantial immediate impact of COVID-19 on current trends, encouraging future examination of long-term effects and ongoing promotion of systemic initiatives to support gender equity.

Artificial intelligence (AI) has many applications in numerous medical fields, including dermatology. Although the majority of AI studies in dermatology focus on skin cancer, there is growing interest in the applicability of AI models in inflammatory diseases, such as psoriasis. Psoriatic disease is a chronic, inflammatory, immune-mediated systemic condition with multiple comorbidities and a significant impact on patients’ quality of life. Advanced treatments, including biologics and small molecules, have transformed the management of psoriatic disease. Nevertheless, there are still considerable unmet needs. Globally, delays in the diagnosis of the disease and its severity are common due to poor access to health care systems. Moreover, despite the abundance of treatments, we are unable to predict which is the right medication for the right patient, especially in resource-limited settings. AI could be an additional tool to address those needs. In this way, we can improve rates of diagnosis, accurately assess severity, and predict outcomes of treatment.

Androgenetic alopecia (AGA) is the most prevalent cause of hair loss around the world.